Charles Schwab Investment Management Inc. boosted its stake in Azenta, Inc. (NASDAQ:AZTA - Free Report) by 11.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 461,603 shares of the company's stock after purchasing an additional 48,064 shares during the period. Charles Schwab Investment Management Inc. owned about 1.01% of Azenta worth $23,080,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Ballentine Partners LLC increased its holdings in Azenta by 2.0% in the fourth quarter. Ballentine Partners LLC now owns 20,340 shares of the company's stock valued at $1,017,000 after purchasing an additional 404 shares during the period. Glenmede Trust Co. NA boosted its position in Azenta by 6.3% during the third quarter. Glenmede Trust Co. NA now owns 11,379 shares of the company's stock valued at $551,000 after acquiring an additional 679 shares during the last quarter. KBC Group NV boosted its position in Azenta by 48.5% during the fourth quarter. KBC Group NV now owns 2,137 shares of the company's stock valued at $107,000 after acquiring an additional 698 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in Azenta by 7.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,700 shares of the company's stock valued at $535,000 after acquiring an additional 702 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its position in Azenta by 4.0% during the third quarter. Victory Capital Management Inc. now owns 27,281 shares of the company's stock valued at $1,321,000 after acquiring an additional 1,061 shares during the last quarter. 99.08% of the stock is currently owned by institutional investors and hedge funds.
Azenta Price Performance
Shares of AZTA stock traded down $0.36 on Friday, reaching $37.43. 1,247,351 shares of the company were exchanged, compared to its average volume of 585,468. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -12.56 and a beta of 1.52. The company has a 50-day moving average of $46.70 and a 200-day moving average of $46.64. Azenta, Inc. has a one year low of $35.56 and a one year high of $63.58.
Azenta (NASDAQ:AZTA - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $0.03. Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. As a group, sell-side analysts predict that Azenta, Inc. will post 0.53 EPS for the current year.
Analysts Set New Price Targets
A number of analysts have commented on AZTA shares. TD Cowen raised shares of Azenta to a "hold" rating in a research report on Thursday, February 27th. Needham & Company LLC upped their price target on shares of Azenta from $55.00 to $59.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Stephens reaffirmed an "overweight" rating and set a $60.00 price target on shares of Azenta in a research report on Thursday, January 2nd. Finally, Evercore ISI increased their price objective on shares of Azenta from $50.00 to $52.00 and gave the stock an "in-line" rating in a research report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Azenta presently has a consensus rating of "Hold" and an average price target of $58.75.
Check Out Our Latest Report on AZTA
About Azenta
(
Free Report)
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Read More
Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
